Bristol-Myers Squibb is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases
With a strong focus on oncology, immunology, cardiology, and fibrotic diseases, the company utilizes advanced science and research to create life-changing therapies. Bristol-Myers Squibb emphasizes collaboration and partnerships with healthcare professionals, researchers, and patients to enhance treatment outcomes and improve quality of life. The company is committed to addressing unmet medical needs through its comprehensive portfolio of prescription medications and is actively engaged in ongoing research to advance healthcare solutions.
Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets.
Biopharmaceutical company Bristol Myers Squibb (NYSEBMY) announced better-than-expected revenue in Q4 CY2024, with sales up 7.5% year on year to $12.34 billion. On the other hand, the company’s full-year revenue guidance of $45.5 billion at the midpoint came in 1.7% below analysts’ estimates. Its non-GAAP profit of $1.67 per share was 13.8% above analysts’ consensus estimates.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top S&P500 gainers and losers in today's pre-market session.
It's a mixed session on Wall Street, with major indices struggling for direction as investors hold their breath ahead of a key jobs report set for Friday morning. The S&P 500 and the Nasdaq 100 edged up 0.3%, while the Dow Jones slipped 0.1% and small caps held steady.
